Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.98
ESALY's Cash-to-Debt is ranked lower than
64% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. ESALY: 0.98 )
Ranked among companies with meaningful Cash-to-Debt only.
ESALY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.3  Med: 0.73 Max: N/A
Current: 0.98
Equity-to-Asset 0.57
ESALY's Equity-to-Asset is ranked lower than
59% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ESALY: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
ESALY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.46 Max: 0.6
Current: 0.57
0.37
0.6
Interest Coverage 21.42
ESALY's Interest Coverage is ranked lower than
65% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. ESALY: 21.42 )
Ranked among companies with meaningful Interest Coverage only.
ESALY' s Interest Coverage Range Over the Past 10 Years
Min: 5.79  Med: 12.96 Max: 1619.43
Current: 21.42
5.79
1619.43
Piotroski F-Score: 5
Altman Z-Score: 3.81
Beneish M-Score: -2.59
WACC vs ROIC
4.54%
10.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 11.48
ESALY's Operating Margin % is ranked higher than
61% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. ESALY: 11.48 )
Ranked among companies with meaningful Operating Margin % only.
ESALY' s Operating Margin % Range Over the Past 10 Years
Min: 2.42  Med: 11.41 Max: 15.61
Current: 11.48
2.42
15.61
Net Margin % 10.37
ESALY's Net Margin % is ranked higher than
65% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. ESALY: 10.37 )
Ranked among companies with meaningful Net Margin % only.
ESALY' s Net Margin % Range Over the Past 10 Years
Min: -2.32  Med: 8.16 Max: 10.47
Current: 10.37
-2.32
10.47
ROE % 9.63
ESALY's ROE % is ranked higher than
60% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. ESALY: 9.63 )
Ranked among companies with meaningful ROE % only.
ESALY' s ROE % Range Over the Past 10 Years
Min: -3.4  Med: 10.2 Max: 16.4
Current: 9.63
-3.4
16.4
ROA % 5.55
ESALY's ROA % is ranked higher than
60% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. ESALY: 5.55 )
Ranked among companies with meaningful ROA % only.
ESALY' s ROA % Range Over the Past 10 Years
Min: -1.78  Med: 4.56 Max: 9.17
Current: 5.55
-1.78
9.17
ROC (Joel Greenblatt) % 29.96
ESALY's ROC (Joel Greenblatt) % is ranked higher than
73% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. ESALY: 29.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ESALY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.99  Med: 27.9 Max: 56.21
Current: 29.96
7.99
56.21
3-Year Revenue Growth Rate -1.60
ESALY's 3-Year Revenue Growth Rate is ranked lower than
74% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. ESALY: -1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ESALY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.6  Med: 7 Max: 15.5
Current: -1.6
-10.6
15.5
3-Year EBITDA Growth Rate -12.10
ESALY's 3-Year EBITDA Growth Rate is ranked lower than
81% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. ESALY: -12.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ESALY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -22.7  Med: 3.7 Max: 45
Current: -12.1
-22.7
45
3-Year EPS without NRI Growth Rate 4.20
ESALY's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. ESALY: 4.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ESALY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -17.3  Med: 6.6 Max: 53.8
Current: 4.2
-17.3
53.8
GuruFocus has detected 4 Warning Signs with Eisai Co Ltd $ESALY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ESALY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ESALY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:OTCPK:SGIOY, OTCPK:MKGAY, OTCPK:MTZPY, OTCPK:APNHF, NYSE:PRGO, OTCPK:HLUYY, NAS:MYL, OTCPK:SFOSF, OTCPK:IPSEY, OTCPK:ORINY, NYSE:RDY, OTCPK:HKMPF, OTCPK:HYPMY, NYSE:TARO, NYSE:MNK, NAS:OPK, NYSE:VRX, NYSE:PTHN, NYSE:ZTS, NYSE:CTLT » details
Traded in other countries:EII.Germany, 4523.Japan,
Headquarter Location:Japan
Eisai Co Ltd is a healthcare company. It is engaged in providing prescription pharmaceuticals, consumer health care products, and diagnostics services.

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Ratios

vs
industry
vs
history
PE Ratio 29.93
ESALY's PE Ratio is ranked lower than
54% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. ESALY: 29.93 )
Ranked among companies with meaningful PE Ratio only.
ESALY' s PE Ratio Range Over the Past 10 Years
Min: 12.4  Med: 24.8 Max: 114.32
Current: 29.93
12.4
114.32
PE Ratio without NRI 29.93
ESALY's PE Ratio without NRI is ranked lower than
55% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. ESALY: 29.93 )
Ranked among companies with meaningful PE Ratio without NRI only.
ESALY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.4  Med: 24.8 Max: 114.33
Current: 29.93
12.4
114.33
Price-to-Owner-Earnings 25.06
ESALY's Price-to-Owner-Earnings is ranked higher than
63% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. ESALY: 25.06 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ESALY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.36  Med: 18.58 Max: 32.62
Current: 25.06
10.36
32.62
PB Ratio 2.77
ESALY's PB Ratio is ranked higher than
53% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. ESALY: 2.77 )
Ranked among companies with meaningful PB Ratio only.
ESALY' s PB Ratio Range Over the Past 10 Years
Min: 1.83  Med: 2.33 Max: 4.2
Current: 2.77
1.83
4.2
PS Ratio 3.10
ESALY's PS Ratio is ranked lower than
52% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ESALY: 3.10 )
Ranked among companies with meaningful PS Ratio only.
ESALY' s PS Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.95 Max: 6.6
Current: 3.1
0.96
6.6
Price-to-Free-Cash-Flow 26.30
ESALY's Price-to-Free-Cash-Flow is ranked lower than
54% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. ESALY: 26.30 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ESALY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 19.97 Max: 206.63
Current: 26.3
5.75
206.63
Price-to-Operating-Cash-Flow 21.45
ESALY's Price-to-Operating-Cash-Flow is ranked lower than
59% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. ESALY: 21.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ESALY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.92  Med: 13.39 Max: 69.65
Current: 21.45
4.92
69.65
EV-to-EBIT 26.51
ESALY's EV-to-EBIT is ranked lower than
65% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. ESALY: 26.51 )
Ranked among companies with meaningful EV-to-EBIT only.
ESALY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.4  Med: 17.25 Max: 85.5
Current: 26.51
9.4
85.5
EV-to-EBITDA 18.63
ESALY's EV-to-EBITDA is ranked lower than
59% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. ESALY: 18.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
ESALY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 10.4 Max: 36.7
Current: 18.63
6.4
36.7
Shiller PE Ratio 29.99
ESALY's Shiller PE Ratio is ranked higher than
68% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. ESALY: 29.99 )
Ranked among companies with meaningful Shiller PE Ratio only.
ESALY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 27.99  Med: 33.54 Max: 39.03
Current: 29.99
27.99
39.03
Current Ratio 2.83
ESALY's Current Ratio is ranked higher than
55% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. ESALY: 2.83 )
Ranked among companies with meaningful Current Ratio only.
ESALY' s Current Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.39 Max: 3.11
Current: 2.83
1.85
3.11
Quick Ratio 2.34
ESALY's Quick Ratio is ranked higher than
58% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. ESALY: 2.34 )
Ranked among companies with meaningful Quick Ratio only.
ESALY' s Quick Ratio Range Over the Past 10 Years
Min: 1.58  Med: 1.96 Max: 2.63
Current: 2.34
1.58
2.63
Days Inventory 143.58
ESALY's Days Inventory is ranked lower than
64% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. ESALY: 143.58 )
Ranked among companies with meaningful Days Inventory only.
ESALY' s Days Inventory Range Over the Past 10 Years
Min: 146.81  Med: 158.37 Max: 170.66
Current: 143.58
146.81
170.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.59
ESALY's Dividend Yield % is ranked higher than
73% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. ESALY: 2.59 )
Ranked among companies with meaningful Dividend Yield % only.
ESALY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.7  Med: 3.99 Max: 6.71
Current: 2.59
1.7
6.71
Dividend Payout Ratio 0.76
ESALY's Dividend Payout Ratio is ranked lower than
83% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. ESALY: 0.76 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ESALY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.48  Med: 0.84 Max: 1.12
Current: 0.76
0.48
1.12
Forward Dividend Yield % 2.40
ESALY's Forward Dividend Yield % is ranked higher than
72% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. ESALY: 2.40 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.58
ESALY's 5-Year Yield-on-Cost % is ranked higher than
60% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. ESALY: 2.58 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ESALY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.7  Med: 3.99 Max: 6.71
Current: 2.58
1.7
6.71
3-Year Average Share Buyback Ratio -0.10
ESALY's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. ESALY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ESALY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2  Med: 0 Max: 1.3
Current: -0.1
-1.2
1.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 39.68
ESALY's Price-to-Net-Current-Asset-Value is ranked lower than
94% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. ESALY: 39.68 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ESALY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 34.61  Med: 52.61 Max: 244.85
Current: 39.68
34.61
244.85
Price-to-Tangible-Book 5.45
ESALY's Price-to-Tangible-Book is ranked lower than
65% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. ESALY: 5.45 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ESALY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.21  Med: 6.25 Max: 19.26
Current: 5.45
4.21
19.26
Price-to-Intrinsic-Value-Projected-FCF 1.61
ESALY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
67% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. ESALY: 1.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ESALY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.05  Med: 1.19 Max: 2.13
Current: 1.61
1.05
2.13
Price-to-Median-PS-Value 1.59
ESALY's Price-to-Median-PS-Value is ranked lower than
76% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ESALY: 1.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ESALY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 1.02 Max: 2.91
Current: 1.59
0.52
2.91
Price-to-Graham-Number 2.69
ESALY's Price-to-Graham-Number is ranked lower than
57% of the 408 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. ESALY: 2.69 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ESALY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.87  Med: 2.6 Max: 4.61
Current: 2.69
1.87
4.61
Earnings Yield (Greenblatt) % 3.77
ESALY's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. ESALY: 3.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ESALY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 5.8 Max: 10.6
Current: 3.77
1.2
10.6
Forward Rate of Return (Yacktman) % -7.55
ESALY's Forward Rate of Return (Yacktman) % is ranked lower than
84% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. ESALY: -7.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ESALY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -13.6  Med: -1.3 Max: 22.4
Current: -7.55
-13.6
22.4

More Statistics

Revenue (TTM) (Mil) $4,883
EPS (TTM) $ 1.76
Beta-0.40
Short Percentage of Float0.00%
52-Week Range $51.43 - 66.92
Shares Outstanding (Mil)285.94
» More Articles for ESALY

Headlines

Articles On GuruFocus.com
Vanguard Adds to Eisai Stake Aug 17 2016 

More From Other Websites
German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx® (lenvatinib) in... Mar 27 2017
Eisai Co., Ltd. :ESALY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 3, 2017 Feb 03 2017
Arena, Eisai Modify Marketing & Supply Agreement for Belviq Jan 05 2017
German Institute for Quality and Efficiency in Health Care (IQWiG) Confirms Additional Benefit for... Jan 04 2017
First-in-class Epilepsy Treatment Fycompa® (perampanel) Launches in Jordan, Kingdom of Saudi Arabia... Jan 03 2017
Merck (MRK) Offers Update on Keytruda-Halaven Combination Dec 13 2016
MediWound (MDWD) in Focus: Stock Moves 23.4% Higher Aug 18 2016
Eisai Co., Ltd. :ESALY-US: Earnings Analysis: Q1, 2017 By the Numbers : August 9, 2016 Aug 09 2016
Biogen, Eisai’s Alzheimer’s Drug E2609 to Enter Late-Stage Trial Aug 09 2016
Eisai: FDA confirms enough data to move Alzheimer's drug to Phase III studies Aug 09 2016
Alcobra (ADHD) Looks Good: Stock Adds 14.4% in Session Aug 04 2016
Rare Cancer Drug Which Significantly Delays Progression of Advanced Thyroid Cancer is Left Off... Aug 01 2016
Eisai Co., Ltd. :ESALY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 Jul 26 2016
Eisai And Arena Pharmaceuticals Get FDA Approval For BELVIQ XR Extended-Release Tablets Jul 19 2016
Eisai, Arena Pharmaceuticals Get Regulatory Approval For VENESPRI In Mexico Jul 14 2016
Eisai Calls for Immediate Solution to Rare Cancers Black Hole Jul 07 2016
ETF’s with exposure to Eisai Co., Ltd. : July 5, 2016 Jul 05 2016
GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1% Jun 24 2016
ETF’s with exposure to Eisai Co., Ltd. : May 19, 2016 May 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)